We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04040725
Recruitment Status : Withdrawn (Withdrawn per Bayer)
First Posted : August 1, 2019
Last Update Posted : December 17, 2019
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Bradley A. McGregor, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Withdrawn
Actual Primary Completion Date : November 27, 2019
Actual Study Completion Date : November 27, 2019